Ligand-Targeted Liposomes for Cancer Treatment

Author(s): Puja Sapra, Pradeep Tyagi, Theresa M. Allen

Journal Name: Current Drug Delivery

Volume 2 , Issue 4 , 2005

Become EABM
Become Reviewer
Call for Editor


Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors expressed on cancer cells is a recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics or gene therapeutics. Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection criteria for the receptors to be targeted, choice of targeting ligands and choice of encapsulated therapeutics. Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. Ligand-targeted liposomes have shown considerable promise in preclinical xenograft models and are poised for clinical development.

Keywords: liposome, immunoliposome, ligand, antibody, cancer, gene therapy, targeted therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [369 - 381]
Pages: 13
DOI: 10.2174/156720105774370159
Price: $65

Article Metrics

PDF: 14